Budesonide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Budesonide

Examples of brand names: Budenofalk [DE]; Pulmicort [DE]

ATC code: A07EA06

Main use (for orientation): Intestinal inflammation; respiratory diseases

Documented research summary

A CBD/CBG/THCV mixture alters budesonide effects inconsistently in lung cell models; no human interaction evidence. The cannabis-smoke/formoterol–budesonide preprint concerns complex smoke and drug combinations, not a pair of isolated substances. CYP3A4/first-pass metabolism provides a theoretical reason for clinical assessment, not a quantified CBD finding.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

Standardised CBD/CBG/THCV mixture (FCBD:std) – laboratory and animal studies

Finding ID: B0333

Type of result: Preclinical combination finding

Observation: Some additional IL-6/IL-8 reduction in A549 monoculture; less consistent in macrophage/co-culture models. No generalisable synergy.

Mechanism: Preclinical anti-inflammatory combination effect in cell models.

Study type: In-vitro 2D/3D inflammation models

Context studied: FCBD:std contains approximately 62.2% CBD, 4.04% CBG and 0.28% THCV; a mixture, not evidence attributable to isolated CBD/CBG/THCV.

Clinical interpretation: No clinical dose or safety conclusion.

Limitations and uncertainties: Not human pharmacokinetics, not an oral colitis preparation; cell concentrations and model dependence limit extrapolation.

Original sources for this finding: Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. [C_PR_36559009]

References and access status

[C_LABEL_D0038_ORAL] Budesonide extended-release tablets [Actavis Pharma]

Original source / bibliographic reference

Authors: Actavis Pharma Inc.

Year: 2024

Source type: US SPL

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_36559009] Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models.

Original source / bibliographic reference

Authors: Vinayaka AC, Shalev N, Anil SM, Tiwari S, Kumar N, Belausov E, Mani KA, Mechrez G, Koltai H.

Year: 2022

Source type: Primary source, relevant full-text sections read

DOI: 10.3390/ph15121559

PMID: 36559009

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_PPR67006] A comparative analysis of cannabis and tobacco smoke exposure on human airway epithelial cell gene expression, immune phenotype, and response to formoterol and budesonide treatment

Original source / bibliographic reference

Authors: Aguiar JA, Huff RD, Tse W, Stampfli MR, McConkey BJ, Doxey AC, Hirota JA.

Year: 2019

Source type: Preprint, abstract read

DOI: 10.1101/516294

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility